Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Buys $19,725.00 in Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) CEO Jay Duker bought 1,500 shares of the stock in a transaction on Monday, March 16th. The shares were acquired at an average cost of $13.15 per share, for a total transaction of $19,725.00. Following the acquisition, the chief executive officer directly owned 100,665 shares in the company, valued at approximately $1,323,744.75. This trade represents a 1.51% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Eyepoint Pharmaceuticals Price Performance

Shares of Eyepoint Pharmaceuticals stock traded up $0.25 during trading hours on Monday, reaching $13.45. The company had a trading volume of 1,106,965 shares, compared to its average volume of 1,445,532. The firm has a market cap of $1.12 billion, a PE ratio of -4.26 and a beta of 1.72. Eyepoint Pharmaceuticals, Inc. has a one year low of $3.91 and a one year high of $19.11. The business has a fifty day simple moving average of $15.32 and a 200 day simple moving average of $14.49.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). The company had revenue of $0.62 million for the quarter, compared to the consensus estimate of $1.01 million. Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%. On average, research analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Jefferies Financial Group Inc. purchased a new position in Eyepoint Pharmaceuticals in the third quarter worth $1,994,000. Corient Private Wealth LLC purchased a new stake in Eyepoint Pharmaceuticals during the second quarter valued at about $1,200,000. Walleye Capital LLC lifted its stake in Eyepoint Pharmaceuticals by 500.6% during the second quarter. Walleye Capital LLC now owns 199,449 shares of the company’s stock worth $1,877,000 after purchasing an additional 166,243 shares during the last quarter. XTX Topco Ltd lifted its stake in Eyepoint Pharmaceuticals by 215.4% during the second quarter. XTX Topco Ltd now owns 137,950 shares of the company’s stock worth $1,298,000 after purchasing an additional 94,210 shares during the last quarter. Finally, Stempoint Capital LP purchased a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth about $3,098,000. Institutional investors own 99.41% of the company’s stock.

Analyst Ratings Changes

EYPT has been the topic of a number of recent analyst reports. Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, November 25th. HC Wainwright boosted their price objective on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Citigroup upped their target price on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Chardan Capital boosted their price target on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Eyepoint Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $32.20.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.